<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(11)</volume><submitter>Ramasamy K</submitter><funding>Janssen-Cilag Ltd, Napp and Blood Cancer UK</funding><journal>Blood cancer journal</journal><pagination>162</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9708638</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.</pubmed_title><pmcid>PMC9708638</pmcid><pubmed_authors>Ramasamy K</pubmed_authors><pubmed_authors>Iqbal G</pubmed_authors><pubmed_authors>Brouwer R</pubmed_authors><pubmed_authors>Stalker V</pubmed_authors><pubmed_authors>Schey S</pubmed_authors><pubmed_authors>Lindsay J</pubmed_authors><pubmed_authors>Akhtar S</pubmed_authors><pubmed_authors>Dunn J</pubmed_authors><pubmed_authors>Drayson M</pubmed_authors><pubmed_authors>Varghese S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.</name><description/><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-05T09:44:04.23Z</modification><creation>2025-04-05T09:44:04.23Z</creation></dates><accession>S-EPMC9708638</accession><cross_references><pubmed>36446771</pubmed><doi>10.1038/s41408-022-00758-7</doi></cross_references></HashMap>